A Phase 1 Study of Eribulin Mesylate With Trastuzumab for Advanced or Recurrent Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Breast Cancer

Trial Profile

A Phase 1 Study of Eribulin Mesylate With Trastuzumab for Advanced or Recurrent Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Breast Cancer

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Oct 2016

At a glance

  • Drugs Eribulin (Primary) ; Trastuzumab (Primary)
  • Indications Breast cancer
  • Focus Adverse reactions
  • Sponsors Eisai Co Ltd
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 13 Jan 2015 According to the ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
    • 16 Jul 2014 Planned End Date changed from 1 Jan 2015 to 1 Sep 2014, according to the ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top